1. Home
  2. ACAD
  3. ACAD News

Latest ACADIA Pharmaceuticals Inc. (ACAD) News on January 19, 2025

ACAD

Argus Research

4 days ago

ACAD: What does Argus have to say about ACAD?

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025
ACAD

GuruFocus.com

5 days ago

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025

ACAD

MT Newswires

5 days ago

Acadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
ACAD

Business Wire

5 days ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
ACAD

Business Wire

5 days ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?
ACAD

Insider Monkey

7 days ago

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%
ACAD

Simply Wall St.

11 days ago

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%

ACAD

MT Newswires

16 days ago

Guggenheim Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $20 From $23

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing
ACAD

Insider Monkey

17 days ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing

ACAD

MT Newswires

19 days ago

Update: Acadia Pharmaceuticals to Replace Independent Bank in S&P SmallCap 600; Acadia Shares Rise

Acadia Pharmaceuticals Set to Join S&P SmallCap 600
ACAD

PR Newswire

19 days ago

Acadia Pharmaceuticals Set to Join S&P SmallCap 600

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024
ACAD

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In December 2024

ACAD

MT Newswires

a month ago

ACADIA Pharmaceuticals Closes Sale of Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
ACAD

Zacks

2 months ago

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
ACAD

Zacks

2 months ago

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options

ACAD Signs License Deal With Saniona for Rights to Neurology Drug
ACAD

Zacks

2 months ago

ACAD Signs License Deal With Saniona for Rights to Neurology Drug

Acadia signs agreement with Saniona to commercialise SAN711
ACAD

Pharmaceutical Technology

2 months ago

Acadia signs agreement with Saniona to commercialise SAN711

ACAD

MT Newswires

2 months ago

Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
ACAD

Business Wire

2 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACAD

Business Wire

2 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

2 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks to Watch in November 2024
ACAD

Simply Wall St.

2 months ago

High Growth Tech Stocks to Watch in November 2024

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
ACAD

Zacks

2 months ago

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next
ACAD

Simply Wall St.

2 months ago

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
ACAD

Simply Wall St.

2 months ago

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
ACAD

GuruFocus.com

2 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
ACAD

Zacks

2 months ago

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates

ACAD

Associated Press Finance

2 months ago

Acadia: Q3 Earnings Snapshot

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
ACAD

Business Wire

2 months ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
ACAD

Business Wire

2 months ago

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024
ACAD

Insider Monkey

3 months ago

ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Health Canada approves Acadia’s DAYBUE for Rett syndrome
ACAD

Pharmaceutical Technology

3 months ago

Health Canada approves Acadia’s DAYBUE for Rett syndrome

ACAD

MT Newswires

3 months ago

ACADIA Pharmaceuticals' Rett Syndrome Treatment Gets Health Canada Approval

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
ACAD

Simply Wall St.

3 months ago

Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

4 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACAD

MT Newswires

4 months ago

Acadia Pharmaceuticals Appoints Catherine Adams as CEO

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
ACAD

Business Wire

4 months ago

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

High Growth Tech Stocks To Watch In September 2024
ACAD

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In September 2024

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
ACAD

Zacks

5 months ago

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Ryan Reynolds Announces More to Parkinson’s® Campaign
ACAD

Business Wire

5 months ago

Ryan Reynolds Announces More to Parkinson’s® Campaign

Shareholders Can Be Confident That ACADIA Pharmaceuticals' (NASDAQ:ACAD) Earnings Are High Quality
ACAD

Simply Wall St.

5 months ago

Shareholders Can Be Confident That ACADIA Pharmaceuticals' (NASDAQ:ACAD) Earnings Are High Quality

ACAD

MT Newswires

5 months ago

UBS Adjusts ACADIA Pharmaceuticals Price Target to $23 From $25, Maintains Buy Rating

ACADIA Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
ACAD

Simply Wall St.

5 months ago

ACADIA Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
ACAD

Investor's Business Daily

5 months ago

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
ACAD

Zacks

5 months ago

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues

ACAD

MT Newswires

5 months ago

Morgan Stanley Downgrades ACADIA Pharmaceuticals to Equalweight From Overweight, Cuts Price Target to $20 From $28

ACAD

MT Newswires

5 months ago

RBC Lowers Price Target on ACADIA Pharmaceuticals to $26 From $29, Keeps Outperform Rating

Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
ACAD

Zacks

5 months ago

Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates

ACAD

Associated Press Finance

5 months ago

Acadia: Q2 Earnings Snapshot

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Analysts Expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) To Breakeven Soon
ACAD

Simply Wall St.

6 months ago

Analysts Expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) To Breakeven Soon

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ACAD

Zacks

6 months ago

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
ACAD

Business Wire

6 months ago

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

ACAD

MT Newswires

7 months ago

BMO Initiates ACADIA Pharmaceuticals at Outperform With $31 Price Target

Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds?
ACAD

Insider Monkey

7 months ago

Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds?

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
ACAD

Business Wire

7 months ago

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
ACAD

GOBankingRates

7 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
ACAD

Business Insider

7 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
ACAD

Insider Monkey

7 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
ACAD

Reuters

7 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

ACAD

Insider Monkey

7 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow
ACAD

AFP

7 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
ACAD

Investor's Business Daily

7 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments
ACAD

The Wall Street Journal

7 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay Rise This Year
ACAD

Simply Wall St.

8 months ago

It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay Rise This Year

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
ACAD

Simply Wall St.

8 months ago

Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

ACAD

GuruFocus.com

8 months ago

ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches

ACAD

MT Newswires

8 months ago

UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating

ACAD

MT Newswires

8 months ago

Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating

ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
ACAD

Simply Wall St.

8 months ago

ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
ACAD

Insider Monkey

8 months ago

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript

ACAD

MT Newswires

8 months ago

Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating

ACAD

GuruFocus.com

8 months ago

ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
ACAD

Zacks

8 months ago

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates

ACAD

Associated Press Finance

8 months ago

Acadia: Q1 Earnings Snapshot

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
ACAD

Zacks

8 months ago

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)
ACAD

GuruFocus.com

9 months ago

Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)

ACAD

MT Newswires

9 months ago

UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago
ACAD

Simply Wall St.

9 months ago

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
ACAD

GuruFocus.com

9 months ago

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
ACAD

Business Wire

10 months ago

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Share on Social Networks: